基于早期肠道微生物群-宿主相互作用模式下初乳口腔护理对早产儿出生后生长的影响

注册号:

Registration number:

ChiCTR2400094495 

最近更新日期:

Date of Last Refreshed on:

2024-12-24 09:28:43 

注册时间:

Date of Registration:

2024-12-24 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于早期肠道微生物群-宿主相互作用模式下初乳口腔护理对早产儿出生后生长的影响

Public title:

The impact of colostrum oral care on the postnatal growth of premature infants based on the early gut microbiota-host interaction model

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于早期肠道微生物群-宿主相互作用模式下初乳口腔护理对早产儿出生后生长的影响

Scientific title:

The impact of colostrum oral care on the postnatal growth of premature infants based on the early gut microbiota-host interaction model

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

汪娜 

研究负责人:

张佳 

Applicant:

Na Wang 

Study leader:

Jia Zhang 

申请注册联系人电话:

Applicant telephone:

+86 183 6015 3339

研究负责人电话:

Study leader's
telephone:

+86 158 5108 5557

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

nawang1026@126.com

研究负责人电子邮件:

Study leader's E-mail:

15851085557@sina.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国江苏省宿迁市宿支路120号

研究负责人通讯地址:

中国江苏省宿迁市宿支路120号

Applicant address:

120 Suzhi Road, Suqian City, Jiangsu Province, China

Study leader's address:

120 Suzhi Road, Suqian City, Jiangsu Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省人民医院宿迁医院

Applicant's institution:

Jiangsu Province (Suqian)Hospital

研究负责人所在单位:

江苏省人民医院宿迁医院

Affiliation of the Leader:

Jiangsu Province (Suqian)Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-SL-0212

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏省人民医院宿迁医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Suqian Hospital, Jiangsu Provincial People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-18 00:00:00

伦理委员会联系人:

李艺

Contact Name of the ethic committee:

Yi Li

伦理委员会联系地址:

中国江苏省宿迁市宿支路120号

Contact Address of the ethic committee:

120 Suzhi Road, Suqian City, Jiangsu Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 159 4915 6940

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏省人民医院宿迁医院

Primary sponsor:

Jiangsu Province (Suqian)Hospital

研究实施负责(组长)单位地址:

中国江苏省宿迁市宿支路120号

Primary sponsor's address:

120 Suzhi Road, Suqian City, Jiangsu Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

宿迁

Country:

China

Province:

Jiangsu provience

City:

单位(医院):

江苏省人民医院宿迁医院

具体地址:

中国江苏省宿迁市宿支路120号

Institution
hospital:

Jiangsu Province (Suqian)Hospital

Address:

120 Suzhi Road, Suqian City, Jiangsu Province, China

经费或物资来源:

宿迁市科技局

Source(s) of funding:

Suqian City Science and Technology Bureau

研究疾病:

宫外发育迟缓  

Target disease:

Extra Uterine Growth Restriction

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.探索初乳口腔护理与极早产儿出生后生长的关系; 2.从早期肠道菌群与宿主相互作用模式中探讨初乳口腔护理与恢复出生体重时间之间的关联。我们的研究最终有助于初乳口腔护理在新生儿重症监护室的实施,实现母乳喂养实践和预防出生后生长不良的目标。  

Objectives of Study:

1. Explore the relationship between colostrum oral care and growth after birth of extremely premature infants; 2. To explore the association between colostrum oral care and the time to regain birth weight from the early intestinal microbiota and host interaction model. Our research ultimately contributes to the implementation of colostrum oral care in neonatal intensive care units, achieving the goals of breastfeeding practice and preventing poor growth after birth.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

48h内死亡;严重出生窒息(定义为脐动脉/第一小时动脉血气pH<7.0);出生合并严重胃肠畸形(如肠闭锁、食管气管瘘、肠旋转异常、先天性巨结肠);产前诊断先天性染色体异常或怀疑先天性遗传代谢性疾病;母亲滥用药物或有母乳喂养禁忌症(HIV等)。

Exclusion criteria:

Death within 48 hours; Severe birth asphyxia (defined as umbilical artery/first hour arterial blood gas pH<7.0); Born with severe gastrointestinal malformations (such as intestinal atresia, esophagotracheal fistula, intestinal rotation abnormalities, and Hirschsprung's disease); Prenatal diagnosis of congenital chromosomal abnormality or suspected congenital genetic metabolic disease; The mother abused drugs or had contraindications to breastfeeding (HIV, etc.).

研究实施时间:

Study execute time:

From 2025-02-01 00:00:00 To 2027-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-02-01 00:00:00 To 2027-12-31 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

110

Group:

Intervention group

Sample size:

干预措施:

在最初的48至72小时内,治疗组所采取的治疗手段如下:使用两个1ml的无菌注射器,分别抽取0.1ml的初乳,并让其在室温下静置5分钟,以恢复至适宜温度供口腔初乳护理使用。随后,移除第一个注射器的尖端与盖子,沿着新生儿右侧口腔黏膜组织,缓缓注入初乳,此过程至少持续20秒。注射完毕后,使用无菌棉签轻拭右侧颊黏膜,时间不少于10秒。第二个注射器则以同样的步骤,在左侧口腔黏膜进行护理。该治疗每3小时进行一次,持续5天。

干预措施代码:

Intervention:

During the first 48 to 72 hours, the treatment group used two sterile 1ml syringes to extract 0.1ml of colostrum and let it rest at room temperature for 5 minutes to restore the appropriate temperature for oral colostrum care. The tip and cap of the first syringe are then removed and the colostrum is slowly injected along the right oral mucosa of the newborn for at least 20 seconds. After the injection, use a sterile cotton swab to gently swab the right cheek mucosa for at least 10 seconds. The second syringe performs the same procedure on the left oral mucosa. The treatment is performed every three hours for five days.

Intervention code:

组别:

对照组

样本量:

110

Group:

Control group

Sample size:

干预措施:

对于对照组,则采用生理盐水替代初乳,操作步骤与治疗组相同。

干预措施代码:

Intervention:

For the control group, normal saline was used instead of colostrum, and the procedure was the same as that of the treatment group.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu Province

City:

单位(医院):

江苏省人民医院宿迁医院 

单位级别:

三甲 

Institution
hospital:

Jiangsu Province (Suqian)Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肠道菌群

指标类型:

次要指标

Outcome:

Extra Uterine Growth Restriction

Type:

Secondary indicator

测量时间点:

出生后1周

测量方法:

16sRNA

Measure time point of outcome:

One week after birth

Measure method:

164RNA

指标中文名:

恢复出生体重时间的组间差异

指标类型:

次要指标

Outcome:

Between-group differences in time to regain birth weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

出院时宫外发育迟缓发生率的组间差异

指标类型:

主要指标

Outcome:

Intergroup differences in the incidence of extrauterine dysplasia at discharge

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

粪便

组织:

Sample Name:

Fecal

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age 34W years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

根据研究中心和胎龄(小于28w或大于等于28w)采用1:1分层区组随机方案,随机序列号是研究开始前通过SAS软件随机生成的(区组长度为6)。统计员准备了密封的、编号的不透明信封,这些信封被分配给各中心研究协调员,他们保证信封是按数字顺序使用的。在收到通知后,各中心研究协调员打开信封,取下小组分配表格,并复印一份表格发送给统计员,底稿留在该患儿病例文件中。

Randomization Procedure (please state who generates the random number sequence and by what method):

According to the study center and gestational age (less than 28w or greater than or equal to 28w), the 1:1 stratified block randomization scheme was adopted. The random serial number was randomly generated by SAS software before the study started (the block length was 6). The statisticians prepared sealed, numbered, opaque envelopes, which were distributed to the centre's research coordinators, who assured that the envelopes were used in numerical order. Upon receipt of the notification, the centre study Coordinator opens the envelope, removes the group assignment form and sends a copy to the statistician, leaving the copy in the child's case file.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

协调中心的数据核查员设计病例观察表。通过CRF表收集围生期特点(胎龄、体重、性别、剖宫产、胎儿宫内窘迫、产前糖皮质激素使用、妊娠期糖尿病、妊娠期高血压、胎膜早破、产房复苏、Apgar评分、入院血气PH值等)、口腔护理过程、入院诊断、诊疗经过(喂养类型、每日肠内外营养摄入量、恢复出生体重时间、达全肠内喂养时间、呼吸支持、抗生素使用等)、并发症(坏死性小肠结肠炎、视网膜病变、支气管肺发育不良、晚发型败血症、脑损伤等)、结局指标(存活、死亡)、出院时生长指标(包括出院体重、出院纠正胎龄、出院头围、出院身长等)。 数据管理系统为自主开发的在线数据库,尚不公开。通过账号密码登陆后填写临床及生物样本数据,数据核查员定期进行数据库维护,进行核查、校正、盲态审核与锁定等全过程。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data checker at the focal point designed the case watch sheet. Perinatal characteristics (gestational age, weight, sex, cesarean section, fetal distress, prenatal glucocorticoid use, gestational diabetes mellitus, gestational hypertension, premature rupture of membrane, delivery room resuscitation, Apgar score, PH value of blood gas on admission, etc.), oral care process, admission diagnosis, diagnosis and treatment process (feeding type, daily intrauterine and intrauterine nutrient intake, recovery, etc.) were collected by CRF table Time to return to birth weight, time to complete enteral feeding, respiratory support, antibiotic use, etc.), complications (NEC of necrotizing enterocolitis, ROP of retinopathy, BPD of bronchopulmonary dysplasia, LOS of late-onset sepsis, brain injury, etc.), outcome indicators (survival, death), growth indicators at discharge (including discharge weight, gestational age of discharge correction, discharge head, etc.) Circumference, discharge length, etc.). The data management system is a self-developed online database, which is not yet open. After logging in through the account and password, fill in the clinical and biological sample data, and the data verifier regularly maintains the database, and carries out the whole process of verification, correction, blind audit and locking.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-12-24 09:28:35